Comparative study of therapeutic effects of Gabapentin versus Levodopa-c on Restless legs syndrome in hemodialysis patientes
Not Applicable
- Conditions
- RLS: Restless Legs syndrome..Other specified extrapyramidal and movement disordersG 25.8
- Registration Number
- IRCT201112078323N1
- Lead Sponsor
- Sponsor name 1 Vice-chancellor of Research and Technology of Kermanshah University of Medical
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusion criteria :minimal time of hemodialysis : 3 mount ?IRLSSG scale more than 10? Patient`s age more than 15 years
Exclusion criteria: Under treatment with psychotropic agents during recent 2 weeks?presence of another neurologic disease comorbid with ESRD for example CVA, MS and etc.?Iron deficiency anemia?Pregnancy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of RLS. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with IRLSSG scale.;Severity of sleep disorder. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with pittsburg sleep quality index.;Quality of life. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with SF-36 (scale of quality of life).;Day time sleepiness. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: Epworth sleepiness scale.
- Secondary Outcome Measures
Name Time Method Drug advers reaction. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with question from patients.